<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075621</url>
  </required_header>
  <id_info>
    <org_study_id>H-23645</org_study_id>
    <nct_id>NCT00075621</nct_id>
  </id_info>
  <brief_title>Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis</brief_title>
  <official_title>A Phase II Trial of Tandem Transplantation in AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Autologous stem cell transplantation may be effective treatment for primary&#xD;
      systemic (AL) amyloidosis.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well tandem (two) autologous stem cell&#xD;
      transplantation works in treating patients with primary systemic (AL) amyloidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the tolerability of tandem autologous stem cell transplantation in patients&#xD;
           with AL amyloidosis.&#xD;
&#xD;
        -  Determine whether this regimen can convert a hematologic non-complete response (CR) to&#xD;
           CR in these patients.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  First transplantation: Patients receive filgrastim (G-CSF) subcutaneously once daily&#xD;
           beginning 3 days before the initiation of stem cell collection and continuing until the&#xD;
           day before the completion of stem cell collection. Patients may undergo bone marrow&#xD;
           harvest if an inadequate number of peripheral blood stem cells are collected.&#xD;
&#xD;
      Patients receive high-dose melphalan IV over 20 minutes on days -3 and -2. Patients undergo&#xD;
      autologous stem cell transplantation (ASCT) on day 0.&#xD;
&#xD;
        -  Second transplantation: Within 6-12 months after the first ASCT, patients not achieving&#xD;
           a complete response receive high-dose melphalan IV over 20 minutes on days -3 and -2 and&#xD;
           a second ASCT on day 0.&#xD;
&#xD;
      Treatment continues in the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 3 and 6 months, 1 year, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2000</start_date>
  <completion_date type="Actual">September 4, 2020</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>100 days, 6 months, and annual</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>tandem transplant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection&#xD;
Drug: melphalan 200 mg/kg over 2 days&#xD;
Procedure/Surgery: autologous peripheral blood stem cell transplantation&#xD;
autologous peripheral blood stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection</description>
    <arm_group_label>tandem transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>200 mg/kg over 2 days</description>
    <arm_group_label>tandem transplant</arm_group_label>
    <other_name>alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous peripheral blood stem cell transplantation</intervention_name>
    <description>autologous peripheral blood stem cell transplantation</description>
    <arm_group_label>tandem transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed AL amyloidosis, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Plasma cell dyscrasia, evidenced by 1 of the following:&#xD;
&#xD;
                    -  Monoclonal protein in the serum or urine by immunofixation electrophoresis&#xD;
&#xD;
                    -  Plasmacytosis of the bone marrow with monoclonal staining for kappa or&#xD;
                       lambda light chain isotype&#xD;
&#xD;
               -  Macroglossia with at least 1 other site having biopsy proven amyloidosis and&#xD;
                  absence of a mutant transthyretin is ruled out&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 1 year&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 45% by MUGA or echocardiogram&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 50%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to tolerate 2 courses of high-dose therapy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior alkylating agent chemotherapy allowed provided there is no morphologic or&#xD;
             cytogenetic evidence of myelodysplastic syndromes&#xD;
&#xD;
          -  Prior total cumulative oral melphalan dose &lt; 300 mg&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic therapy and recovered&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No senile, secondary, localized, dialysis-related, or familial amyloidosis&#xD;
&#xD;
          -  No overt multiple myeloma (e.g., greater than 30% bone marrow plasmacytosis, extensive&#xD;
             [more than 2] lytic lesions, hypercalcemia)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No arrhythmia refractory to therapy&#xD;
&#xD;
          -  No evidence of symptomatic transient ischemic attacks or strokes&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer currently in complete remission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaishali Sanchorawala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research Center at Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary systemic amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

